ZYXI vs. AXGN, EDAP, SMLR, ELMD, OM, FONR, VANI, CUTR, BLFS, and SLNO
Should you be buying Zynex stock or one of its competitors? The main competitors of Zynex include AxoGen (AXGN), Edap Tms (EDAP), Semler Scientific (SMLR), Electromed (ELMD), Outset Medical (OM), FONAR (FONR), Vivani Medical (VANI), Cutera (CUTR), BioLife Solutions (BLFS), and Soleno Therapeutics (SLNO). These companies are all part of the "electromedical equipment" industry.
AxoGen (NASDAQ:AXGN) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
AxoGen presently has a consensus price target of $10.67, indicating a potential upside of 66.41%. Zynex has a consensus price target of $18.00, indicating a potential upside of 64.08%. Given Zynex's higher possible upside, equities analysts clearly believe AxoGen is more favorable than Zynex.
AxoGen has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.
AxoGen received 424 more outperform votes than Zynex when rated by MarketBeat users. Likewise, 72.59% of users gave AxoGen an outperform vote while only 50.00% of users gave Zynex an outperform vote.
Zynex has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
Zynex has a net margin of 5.28% compared to Zynex's net margin of -13.66%. AxoGen's return on equity of 16.82% beat Zynex's return on equity.
80.3% of AxoGen shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 7.2% of AxoGen shares are owned by company insiders. Comparatively, 52.1% of Zynex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Zynex had 8 more articles in the media than AxoGen. MarketBeat recorded 11 mentions for Zynex and 3 mentions for AxoGen. AxoGen's average media sentiment score of 0.05 beat Zynex's score of 0.00 indicating that Zynex is being referred to more favorably in the news media.
Summary
Zynex beats AxoGen on 11 of the 17 factors compared between the two stocks.
Get Zynex News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZYXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
